Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells - PubMed (original) (raw)
. 2006 Mar 15;118(6):1404-13.
doi: 10.1002/ijc.21539.
Affiliations
- PMID: 16206268
- DOI: 10.1002/ijc.21539
Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells
Daniela Baus et al. Int J Cancer. 2006.
Abstract
The essential regulators in the pathogenesis of classical Hodgkin lymphoma (cHL) are still largely unknown. The malignant Hodgkin/Reed-Sternberg (HRS) cells of cHL secrete various cytokines leading to the activation of signaling pathways such as the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. In this study, we investigate the role of distinct JAK/STAT pathway components in the regulation of proliferation and survival of cHL cell lines. Electrophoretic mobility shift assay and western blot analysis revealed that the activation status of STAT family members varies in different cHL cell lines. Tyrosine kinase inhibitors of the JAK/STAT pathway blocked the activation of most of the STAT family members. This was accompanied with a strong antiproliferative effect and enhanced death of the treated cHL cell lines. Specific downregulation of STAT3 by siRNA expression decreased cell proliferation and induced apoptosis. Overexpression of SOCS1 and SOCS3 resulted in a proliferation arrest of cells with limited endogenous amount of these negative regulators, but not in cells that already express high amounts of SOCS1 and SOCS3. Our findings highlight the importance of STAT3 in cHL transformation and suggest SOCS1 and SOCS3 as potential targets for therapeutic intervention in distinct forms of cHL.
Similar articles
- Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Gao SM, Chen CQ, Wang LY, Hong LL, Wu JB, Dong PH, Yu FJ. Gao SM, et al. Exp Hematol. 2013 Mar;41(3):261-70.e4. doi: 10.1016/j.exphem.2012.10.012. Epub 2012 Oct 27. Exp Hematol. 2013. PMID: 23111066 - STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis.
Holtick U, Vockerodt M, Pinkert D, Schoof N, Stürzenhofecker B, Kussebi N, Lauber K, Wesselborg S, Löffler D, Horn F, Trümper L, Kube D. Holtick U, et al. Leukemia. 2005 Jun;19(6):936-44. doi: 10.1038/sj.leu.2403750. Leukemia. 2005. PMID: 15912144 - Acute alcohol intake induces SOCS1 and SOCS3 and inhibits cytokine-induced STAT1 and STAT3 signaling in human monocytes.
Norkina O, Dolganiuc A, Catalano D, Kodys K, Mandrekar P, Syed A, Efros M, Szabo G. Norkina O, et al. Alcohol Clin Exp Res. 2008 Sep;32(9):1565-73. doi: 10.1111/j.1530-0277.2008.00726.x. Epub 2008 Jul 9. Alcohol Clin Exp Res. 2008. PMID: 18616672 Free PMC article. - Hepatocyte growth control by SOCS1 and SOCS3.
Khan MGM, Ghosh A, Variya B, Santharam MA, Kandhi R, Ramanathan S, Ilangumaran S. Khan MGM, et al. Cytokine. 2019 Sep;121:154733. doi: 10.1016/j.cyto.2019.154733. Epub 2019 May 30. Cytokine. 2019. PMID: 31154249 Review. - SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation.
Davey GM, Heath WR, Starr R. Davey GM, et al. Tissue Antigens. 2006 Jan;67(1):1-9. doi: 10.1111/j.1399-0039.2005.00532.x. Tissue Antigens. 2006. PMID: 16451196 Review.
Cited by
- The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.
Derenzini E, Lemoine M, Buglio D, Katayama H, Ji Y, Davis RE, Sen S, Younes A. Derenzini E, et al. Blood Cancer J. 2011 Dec;1(12):e46. doi: 10.1038/bcj.2011.46. Epub 2011 Dec 2. Blood Cancer J. 2011. PMID: 22829094 Free PMC article. - The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Buglio D, Mamidipudi V, Khaskhely NM, Brady H, Heise C, Besterman J, Martell RE, MacBeth K, Younes A. Buglio D, et al. Br J Haematol. 2010 Nov;151(4):387-96. doi: 10.1111/j.1365-2141.2010.08342.x. Epub 2010 Sep 29. Br J Haematol. 2010. PMID: 20880107 Free PMC article. - Hodgkin Lymphoma: A Special Microenvironment.
Opinto G, Agostinelli C, Ciavarella S, Guarini A, Maiorano E, Ingravallo G. Opinto G, et al. J Clin Med. 2021 Oct 12;10(20):4665. doi: 10.3390/jcm10204665. J Clin Med. 2021. PMID: 34682791 Free PMC article. Review. - Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.
Dickinson M, Johnstone RW, Prince HM. Dickinson M, et al. Invest New Drugs. 2010 Dec;28 Suppl 1(Suppl 1):S3-20. doi: 10.1007/s10637-010-9596-y. Epub 2010 Dec 14. Invest New Drugs. 2010. PMID: 21161327 Free PMC article. Review. - Genomic alterations in Hodgkin's lymphoma.
Weniger MA, Barth TF, Möller P. Weniger MA, et al. Int J Hematol. 2006 Jun;83(5):379-84. doi: 10.1532/IJH97.06048. Int J Hematol. 2006. PMID: 16787866 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous